Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Arctic Bioscience AS ( (DE:9TD) ) just unveiled an announcement.
Arctic Bioscience’s recent analysis from the HeROPA study indicates that their drug candidate, HRO350, shows significant promise in reducing systemic inflammation in patients with mild to moderate psoriasis. The findings suggest that HRO350 not only improves skin symptoms and quality of life but also holds potential for broader anti-inflammatory applications, positioning it as a promising treatment option in the market. The company plans to leverage these results in commercial discussions with potential partners, highlighting the drug’s safety and efficacy.
More about Arctic Bioscience AS
Arctic Bioscience is a biotechnology company that develops and commercializes pharmaceutical products and dietary supplements based on unique bioactive marine raw materials. The company is focused on developing HRO350, a new oral drug candidate for treating mild-to-moderate psoriasis, and sells dietary supplements globally under the brand ROMEGA®.
Average Trading Volume: 72,149
Current Market Cap: NOK89.98M
See more insights into 9TD stock on TipRanks’ Stock Analysis page.